Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss

Alterations of the Retinoblastoma (Rb) pathway are frequent in ovarian cancer, typically resulting from CDKN2A down-regulation, CCNE1 amplification, CCND1/2 amplification, and RB1 loss. However, bi-allelic CDKN2A mutation or homozygous deletion is a very rare event, concerning less than 5% of patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Frisone, Daniele, Charrier, Melinda, Clement, Sophie, Christinat, Yann, Thouvenin, Laure, Homicsko, Krisztian, Michielin, Olivier, Bodmer, Alexandre, Chappuis, Pierre O., McKee, Thomas A., Tsantoulis, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Bedside-to-Bench Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012162/
https://www.ncbi.nlm.nih.gov/pubmed/31709901
http://dx.doi.org/10.1080/15384047.2019.1685291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012162/
https://www.ncbi.nlm.nih.gov/pubmed/31709901
http://dx.doi.org/10.1080/15384047.2019.1685291

Ejemplares similares